trial

Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment

NCTId NCT00428168
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 36 (actual)
Sponsored by OBEcure Ltd.
Primary completion 2008-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-03
Primary completion
2008-08
Eligibility
ALL · 16 Years · 45 Years

Interventions & indications

Drugs
Betahistine

Sponsors

OBEcure Ltd.Lead Sponsor

Investigators

1
Yaffa BeckStudy Chair

Sites

10 total
Edmonton, CanadaPenticton, CanadaVictoria, CanadaWinnipeg, CanadaHalifax, CanadaKingston, CanadaVerdun (Montreal), CanadaBat Yam, IsraelPetah Tikva, IsraelTirat Hacarmel, Israel

Linked catalysts

1
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine — primary completion2008-08

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE2
Primary Completion Date
2008-08
Status
TERMINATED
relationships
The graph out of here
drug
Betahistine
drug
lead_sponsor
OBEcure Ltd.
company
indication
Obesity
indication
Schizophrenia
indication
Weight Gain
indication
investigator
Yaffa Beck
person